<DOC>
	<DOC>NCT00401622</DOC>
	<brief_summary>To assess the clinical benefits of the OneTouch® Ultra®2 BGMS versus standard BGMS during 52 weeks of use.</brief_summary>
	<brief_title>Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>· Current diagnosis of type 2 diabetes Diagnosed at least 3 months prior to the start of the study but not more than 15 years from the start of the study Stable regimen (i.e., no changes in therapeutic regimen) for the past three months Baseline HbA1c of 7.0 to 8.9%, inclusive Using insulin Using oral agents that target postprandial hyperglycemia (Note: These medications may be added during the study) Known history of anemia or disorders associated with anemia Has previously used the devices being tested in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>